World Antibiotics Awareness Week focuses on the threat of antibiotic resistance to key...
Antibiotic-resistant-related deaths are decreasing while infections are on the rise
More than 2.8 million antibiotic-resistant infections occur in the US each year.
Early-stage pipeline shows a diversity of targets in cancer immune targeting
The age of immuno-oncology has only just started.
World Antibiotic Awareness Week: tackling multi-drug resistant bacteria
World Antibiotics Awareness Week focuses on the threat of antibiotic resistance to key part. A key part of solving the AMR crisis is to develop novel therapies to tackle resistance, particularly targeting those bacteria that are resistant to multiple antibiotics. One innovative approach is leveraging biology to create phage-based therapies.
Jazz Pharma’s sleepiness drug solriamfetol gets CHMP recommendation
Jazz Pharmaceuticals has secured a positive opinion from a European Medicines Agency (EMA) panel for solriamfetol to improve wakefulness and decrease excessive daytime sleepiness (EDS) in adults with narcolepsy or obstructive sleep apnoea (OSA).
Promising results for Novartis’s Entresto in HFpEF sub-populations
Novartis has announced its heart failure drug Entresto (sacubitril/valsartan) causes a greater reduction in heart failure hospitalisation and cardiovascular (CV) deaths compared to valsartan alone in women with heart failure with preserved ejection fraction (HFpEF).
Beigene receives its first FDA approval for a MCL drug
Chinese-headquartered Beigene has announced the US Food and Drug Administration (FDA) has approved Brukinsa (zanubrutinib) to treat patients with relapsed or refractory mantle cell lymphoma (MCL), making this the first Beigene-discovered product to gain FDA approval.
Sarepta and StrideBio sign gene therapy development deal
Sarepta Therapeutics has partnered with StrideBio for the development of in-vivo adeno-associated viral (AAV) based therapies for up to eight targets of the central nervous system (CNS) and neuromuscular conditions.
Bayer to invest $100m for alliance with Dewpoint Therapeutics
Bayer has entered an option, research and licence agreement valued at approximately $100m with Dewpoint Therapeutics to develop therapies for cardiovascular and gynaecological conditions.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.